FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(the “Company”)

([illegible])

Terms of Reference and Implementation Rules of the Environmental, Social and Governance Committee under the Board of Directors

Chapter 1 General Provisions

Article 1 [illegible]

Chapter 2 Composition

Article 2 [illegible]

Article 3 [illegible]

Article 4 [illegible]

Article 5 T e ESG C ee a a e e a e e f ff ce a e b a d f d ec . T e e f ff ce f e be e e ab e -e ec D c f e be e ac a d ec f e C , a , e a a a ca e e ff ce a e be f e da e f e Me be a a , e b a d f d ec f e e , f e e f ff ce. T e b a d f d ec a , af e c e be a e e ff ce e e f c e be a bee a ed, f e aca e acc da ce e e a f e R e .

Article 6 T e ESG C ee a e ab a a a f , e e e ESG a e a e a ed .

T e ESG C ee a a e e ec e a a e c a a f e ESG C ee da .

Chapter 3 Duties and Po ers

Article 7 T e a d e a e f e ESG C ee a e:

(I) F a f ESG be c e , a e e a c c e

1. de e , a a e e G ' ESG be c e , a e e a c c e, a a e ec e da e b a d f d ec e e a ESG ; a

2. de f ESG- e a ed e a a e a f ca , ac e G ' e a a d/ e e e f e e a e de .

(II) Re e e e a f ESG a e a c c e

1. e e e ac a ac e e e f e G ' ESG ba ed a , a e a da d , f a e a e e a e a ad e e ac be a e , e f a ce;

2. e c a a ea f c ca e G ' a e de a e e a e e a , ce a e ace effec e , e e e a be ee e G a a e de a ec e G ' e a ; a

3. e e e ESG e a e a ed a , a a e e ade ac a effec e f e G ' ESG c c e acc d , a , e e ce a , ad a da e e G ' ESG ce e e c ce a e da e a c a ce a cab e a a e a , e a e e e a e a a da d .

(III) O er

1. re e e ESG a a e r a d ec e d ec f c ac r dec f r e c de a f e b a d f d ec r r de a a e e f e ESG e r ; a d

2. e e a a ESG Re r e a ed b e b a d f d ec r acc da ce e SEHK L R e e C r a e G e a ce C de (e A e d 14 e SEHK L R e) a d e E r e a S c a a d G e a ce Re r G de (e A e d 27 e SEHK L R e) c ded e C a a a e r r b ed e a a e .

Chapter 4 Decision-making Procedures

Article 8 T e r r a be e be f r de a r e e a a r r f r dec a b e ESG C ee, a d r d e e a r e a f e G r .

Article 9 T e ESG C ee acc abe e b a d f d ec r a d r a a d e r a be b ed e b a d f d ec r f r c de a dec a d a r a .

Chapter 5 Rules of Procedures

Article 10 Mee f e ESG C ee a c de e a ee a d e ee . Re a ee a be c e ed a ea ce a ea e ea e ee a be c e ed r a b e c a a f e c ee e a -a f f e be .

Article 11 N ce f ee f e ESG C ee a be ade a e be r ee da r r e ee . T e ee a be e ded e b e c a a f e c ee a d e c a a f abe a e d a a a e de e de e ec e d ec r e de e e ee .

Article 12 Mee f e ESG C ee a be e d b r e a - d f e e be a e d e ee e Eac e be a . Re ad ed a e ee a be a ed b r e a -a f f a e be (c d e be e e a e ee).

Article 13 T e ESG C ee a e a f a d r a a e ee . Mee a be c e ed e f f c ca e e e r ded a e e be a f e e e e r .

Article 14 [illegible] ESG Committee [illegible] CFO [illegible]

Article 15 [illegible] ESG Committee [illegible]

Article 16 [illegible] ESG Committee [illegible] SSE [illegible] SEHK [illegible]

Article 17 [illegible] ESG Committee [illegible]

Article 18 [illegible] ESG Committee [illegible]

Article 19 [illegible]

Chapter 6 Supplementary Provisions

Article 20 [illegible] SSE [illegible] SEHK [illegible]

Article 21 [illegible]

Article 22 [illegible]

[illegible]

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

30 March 2020

[illegible]

* *[illegible]*